Brett E Crawford
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2005First federal award
$5.3MFederal grants as PI13 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
13 awards · $5.3M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Jul 15, 2012 | NIH | SBIR/STTR Phase I Development of a Small Molecule Therapy for Metachromatic Leukodystrophy | $296K | Zacharon Pharmaceuticals Inc. |
| Apr 1, 2012 | NIH | SBIR/STTR Phase I Development of a Novel Biomarker for Mucopolysaccharidosis I, II, and VI | $336K | Zacharon Pharmaceuticals Inc. |
| Feb 1, 2011 | NIH | SBIR/STTR Phase I A Novel Small Molecule Therapy for Tay-Sachs and Sandhoff Diseases | $343K | Zacharon Pharmaceuticals Inc. |
| May 17, 2010 | NIH | SBIR/STTR Phase I Substrate Optimization Therapy: A Novel Therapy for Mucopolysaccharidosis | $340K | Zacharon Pharmaceuticals Inc. |
| May 17, 2010 | NIH | SBIR/STTR Phase II Substrate Optimization Therapy: A Novel Therapy for Mucopolysaccharidosis | $999K | Zacharon Pharmaceuticals Inc. |
| May 17, 2010 | NIH | SBIR/STTR Phase II Substrate Optimization Therapy: A Novel Therapy for Mucopolysaccharidosis | $1000K | Zacharon Pharmaceuticals Inc. |
| Jul 1, 2006 | NIH | SBIR/STTR Phase II Development of Novel Inhibitors of Ganglioside Biosynthesis | $106K | Zacharon Pharmaceuticals Inc. |
| Jul 1, 2006 | NIH | SBIR/STTR Phase II Development of Novel Inhibitors of Ganglioside Biosynthesis | $175K | Zacharon Pharmaceuticals Inc. |
| Jul 1, 2006 | NIH | SBIR/STTR Phase II Development of Novel Inhibitors of Ganglioside Biosynthesis | $652K | Zacharon Pharmaceuticals Inc. |
| Jul 1, 2006 | NIH | SBIR/STTR Phase II Development of Novel Inhibitors of Ganglioside Biosynthesis | $697K | Zacharon Pharmaceuticals Inc. |
| Jul 1, 2006 | NIH | NIH R21 Development of cell-based assays for discovery of GIcNAc-TV inhibitors. | $125K | Zacharon Pharmaceuticals Inc. |
| Jul 1, 2006 | NIH | SBIR/STTR Phase I Development of a cell-based screen for inhibitors of ganglioside biosynthesis | $100K | Zacharon Pharmaceuticals Inc. |
| Sep 30, 2005 | NIH | NIH R21 Cell-Based Screen-Inhibitors of Mucin-Type O-Linked(RMI) | $125K | Zacharon Pharmaceuticals Inc. |
1 patents as inventor
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#250
Awards as PI#72
Patents#273
Companies
- Zacharon Pharmaceuticals Inc.Linked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.